The 2020 WHO classification of tumors of soft tissue: selected changes and new entities
JH Choi, JY Ro - Advances in Anatomic Pathology, 2021 - journals.lww.com
Soft tissue tumors are a relatively rare and diagnostically challenging group of neoplasms
that can have varying lines of differentiation. Accurate diagnosis is important for appropriate …
that can have varying lines of differentiation. Accurate diagnosis is important for appropriate …
The 2020 WHO classification: what's new in soft tissue tumor pathology?
ME Kallen, JL Hornick - The American journal of surgical …, 2021 - journals.lww.com
The fifth edition of the World Health Organization Classification of Tumors of Soft Tissue and
Bone was published in early 2020. The revisions reflect a consensus among an …
Bone was published in early 2020. The revisions reflect a consensus among an …
[HTML][HTML] Molecular characterization of cancers with NTRK gene fusions
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients
with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently …
with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently …
Updates from the 2020 World Health Organization classification of soft tissue and bone tumours
The fifth edition of the World Health Organization (WHO) classification of soft tissue and
bone tumours was published in May 2020. This 'Blue Book', which is also available digitally …
bone tumours was published in May 2020. This 'Blue Book', which is also available digitally …
The current state of molecular testing in the treatment of patients with solid tumors, 2019
The world of molecular profiling has undergone revolutionary changes over the last few
years as knowledge, technology, and even standard clinical practice have evolved. Broad …
years as knowledge, technology, and even standard clinical practice have evolved. Broad …
[HTML][HTML] Identifying patients with NTRK fusion cancer
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent
Food and Drug Administration approval of larotrectinib, it is now clinically important to …
Food and Drug Administration approval of larotrectinib, it is now clinically important to …
Developments of CRBN-based PROTACs as potential therapeutic agents
C Wang, Y Zhang, Y Wu, D **ng - European journal of medicinal chemistry, 2021 - Elsevier
Protease-targeted chimeras (PROTACs) are a new technology that is receiving much
attention in the treatment of diseases. The mechanism is to inhibit protein function by …
attention in the treatment of diseases. The mechanism is to inhibit protein function by …
[HTML][HTML] Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy
SJ Hsiao, A Zehir, AN Sireci, DL Aisner - The Journal of Molecular …, 2019 - Elsevier
Chromosomal rearrangements involving the NTRK1, NTRK2, and NTRK3 genes (NTRK
genes), which encode the high-affinity nerve growth factor receptor (TRKA), brain-derived …
genes), which encode the high-affinity nerve growth factor receptor (TRKA), brain-derived …
Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms
JP Solomon, JF Hechtman - Cancer research, 2019 - AACR
Oncogenic fusions involving NTRK1, NTRK2, and NTRK3 with various partners are
diagnostic of infantile fibrosarcoma and secretory carcinoma yet also occur in lower …
diagnostic of infantile fibrosarcoma and secretory carcinoma yet also occur in lower …
Testing algorithm for identification of patients with TRK fusion cancer
The neurotrophic tyrosine receptor kinase (NTRK) gene family encodes three tropomyosin
receptor kinases (TRKA, TRKB, TRKC) that contribute to central and peripheral nervous …
receptor kinases (TRKA, TRKB, TRKC) that contribute to central and peripheral nervous …